ArticlePharmacoEconomics2018

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Guy Neff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.